Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [ Lu]Lu-PSMA-617 Radioligand Therapy.

 [ Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying high-risk patients is crucial. We evaluated pretherapeutic PSMA PET-derived parameters to predict prostate-specific antigen (PSA) response in patients undergoing [ Lu]Lu-PSMA-617 RLT.

Radiosynthesis and preclinical evaluation of a Ga-labeled tetrahydroisoquinoline-based ligand for PET imaging of C-X-C chemokine receptor type 4 in an animal model of glioblastoma.

Background: This study aimed to develop a novel positron emission tomography (PET) tracer, [Ga]Ga-TD-01, for CXCR4 imaging. To achieve this goal, the molecular scaffold of TIQ15 was tuned by conjugation with the DOTA chelator to make it suitable for Ga radiolabeling.

Methods: A bifunctional chelator was prepared by conjugating the amine group of TIQ15 with p-NCS-Bz-DOTA, yielding TD-01, with a high yield (68.

Head-to-head comparison of F-FDG and F-FES PET/CT for initial staging of ER-positive breast cancer patients.

Purpose: To compare the diagnostic performance of F-fluorodeoxyglucose (F-FDG) and F-fluoroestradiol (F-FES) positron emission tomography/computed tomography (PET/CT) for initial staging of estrogen receptor (ER) positive breast cancer.

Methods: Twenty-eight patients with ER-positive breast cancer underwent F-FDG and F-FES PET/CT for initial staging. Diagnostic performance and concordance rates were analyzed for both radiotracers.

Head-to-Head Comparison of Ga-FAPI-46 and F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study.

Ga-conjugated fibroblast activation protein inhibitor (Ga-FAPI) has become an attractive agent for PET. This study aimed to compare Ga-FAPI-46 PET/CT with F-FDG PET/CT for detecting primary cancer and metastatic lesions in patients with head and neck squamous cell carcinoma (HNSCC). Twelve patients and 28 patients with HNSCC underwent Ga-FAPI-46 and F-FDG PET/CT for initial staging and recurrence detection, respectively.

The Evaluation of Tau Deposition with [F]PI-2620 by Using a Semiquantitative Method in Cognitively Normal Subjects and Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Background: Some studies have reported the effectiveness of [F]PI-2620 as an effective tau-binding radiotracer; however, few reports have applied semiquantitative analysis to the tracer. Therefore, this study's aim was to perform a semiquantitative analysis of [F]PI-2620 in individuals with normal cognition and patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD).

Methods: Twenty-six cognitively normal (CN) subjects, 7 patients with AD, and 36 patients with MCI were enrolled.